Cargando…

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia

BACKGROUND: Although many studies have reported that glucose and lipid metabolism disorders are a significant side effect associated with the use of antipsychotic drugs, the characteristics of glucose and lipid metabolism disorders in patients with schizophrenia who are taking antipsychotic drugs re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiaoli, Huang, Zeping, Han, Hongying, Zhong, Zhiyong, Gan, Zhaoyu, Guo, Xiaofeng, Diao, Feici, Han, Zili, Zhao, Jingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114900/ https://www.ncbi.nlm.nih.gov/pubmed/25092981 http://dx.doi.org/10.2147/NDT.S63140

Ejemplares similares

Neuroanatomical correlates of psychopathology in antipsychotic-naïve schizophrenia
por: Venkatasubramanian, Ganesan
Publicado: (2010)

Thalamic Shape Abnormalities in Antipsychotic Naïve Schizophrenia
por: Danivas, Vijay, et al.
Publicado: (2013)

Entorhinal Cortex Volume in Antipsychotic-naïve Schizophrenia
por: Jose, Sam P., et al.
Publicado: (2012)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Validation of the Chinese version of the "Mood Disorder Questionnaire" for screening bipolar disorder among patients with a current depressive episode
por: Gan, Zhaoyu, et al.
Publicado: (2012)

Correction: Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
Publicado: (2020)

Osteoporosis Associated with Antipsychotic Treatment in Schizophrenia
por: Wu, Haishan, et al.
Publicado: (2013)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients
por: Wang, Juan, et al.
Publicado: (2013)

Predictors of successful discontinuation of antipsychotics and antidepressants
por: Lincoln, Tania M., et al.
Publicado: (2023)

Volume alteration of hippocampal subfields in first-episode antipsychotic-naïve schizophrenia patients before and after acute antipsychotic treatment
por: Li, Wenbin, et al.
Publicado: (2018)

Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients
por: Chadda, Rakesh K., et al.
Publicado: (2013)

Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia
por: Anhøj, Simon, et al.
Publicado: (2018)

The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
por: Grošić, Vladimir, et al.
Publicado: (2014)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Grey matter connectome abnormalities and age-related effects in antipsychotic-naive schizophrenia
por: Yang, Beisheng, et al.
Publicado: (2021)

Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
por: Stam, Noraly, et al.
Publicado: (2020)

Impaired interactions among white‐matter functional networks in antipsychotic‐naive first‐episode schizophrenia
por: Fan, Yun‐Shuang, et al.
Publicado: (2019)

Anterior Cingulate Cortex Glutamate Levels Are Related to Response to Initial Antipsychotic Treatment in Drug-Naive First-Episode Schizophrenia Patients
por: Li, Jinguang, et al.
Publicado: (2020)

Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
por: Mahlich, Jörg, et al.
Publicado: (2020)

Pars Triangularis Volume Asymmetry and Schneiderian First Rank Symptoms in Antipsychotic-naïve Schizophrenia
por: Shivakumar, Venkataram, et al.
Publicado: (2021)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Association between Serum Lipids and Antipsychotic Response in Schizophrenia
por: Kim, David D., et al.
Publicado: (2019)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Orbitofrontal Lobe Volume Deficits in Antipsychotic-Naïve Schizophrenia: A 3-Tesla MRI study
por: Behere, Rishikesh V., et al.
Publicado: (2009)

Magnetization transfer imaging alterations and its diagnostic value in antipsychotic-naïve first-episode schizophrenia
por: Lei, Du, et al.
Publicado: (2022)

Positive Symptoms in Antipsychotic-naïve Schizophrenia are Associated with Increased Body Mass Index after Treatment
por: Lin, Shih-Hsien, et al.
Publicado: (2021)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Comparative effectiveness of antipsychotic drugs in schizophrenia
por: Stroup, T. Scott, et al.
Publicado: (2000)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Antipsychotic agents: efficacy and safety in schizophrenia
por: de Araújo, Arão Nogueira, et al.
Publicado: (2012)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
por: Kamei, Hiroyuki
Publicado: (2022)

Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
por: Cooper, Ruth E., et al.
Publicado: (2019)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia
por: Correia, Banny Silva Barbosa, et al.
Publicado: (2021)

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
por: Crellin, Nadia E., et al.
Publicado: (2022)

Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10
por: Tatini, Lorenzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ta2qg97icpka4ucjmm6u023n45